Y-mAbs Therapeutics (YMAB) Insider Trading & Ownership $10.41 +0.31 (+3.07%) (As of 11/22/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Y-mAbs Therapeutics (NASDAQ:YMAB) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage22.50%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)$1.41 MNumber OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$3.23 M Get YMAB Insider Trade Alerts Want to know when executives and insiders are buying or selling Y-mAbs Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address YMAB Insider Buying and Selling by Quarter Ad True Market Insiders25X predicted for “Amazon Coin” – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team of crypto experts has identified it as the most promising crypto of 2024. You can see all of the details surrounding the #1 Crypto of 2024>3-Cent Amazon Coin< Y-mAbs Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails9/16/2024Thomas GadInsiderSell30,000$12.97$389,100.00 9/13/2024Thomas GadInsiderSell65,000$13.47$875,550.00 8/26/2024Joris WilmsCOOSell5,000$14.69$73,450.00 6/10/2024Gerard BerDirectorSell722$12.00$8,664.00 6/10/2024Thomas GadInsiderSell35,000$12.03$421,050.00 5/31/2024Bo KruseCFOSell31,371$12.07$378,647.97 A “Thank You Gift” From Pres. Trump - Genius (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide5/23/2024Thomas GadInsiderSell7,351$13.00$95,563.00 5/21/2024Thomas GadInsiderSell25,000$12.00$300,000.00 3/5/2024Vignesh RajahSVPSell1,711$16.53$28,282.83 12/15/2023Thomas GadInsiderSell50,000$6.61$330,500.00 12/13/2023Thomas GadInsiderSell50,000$6.58$329,000.00 12/11/2023Biotech Aps WgDirectorBuy102,863$7.01$721,069.63 12/7/2023Biotech Aps WgDirectorBuy6,183$6.50$40,189.50 11/29/2023Biotech Aps WgDirectorBuy51,837$5.97$309,466.89 11/27/2023Johan Wedell-WedellsborgDirectorBuy62,516$5.49$343,212.84 (Data available from 1/1/2013 forward) YMAB Insider Trading Activity - Frequently Asked Questions Who is on Y-mAbs Therapeutics's Insider Roster? The list of insiders at Y-mAbs Therapeutics includes Biotech Aps Wg, Bo Kruse, Gerard Ber, Johan Wedell-Wedellsborg, Joris Wilms, Thomas Gad, and Vignesh Rajah. Learn more on insiders at YMAB. What percentage of Y-mAbs Therapeutics stock is owned by insiders? 22.50% of Y-mAbs Therapeutics stock is owned by insiders. Learn more on YMAB's insider holdings. Which Y-mAbs Therapeutics insiders have been buying company stock? The following insiders have purchased YMAB shares in the last 24 months: Biotech Aps Wg ($1,070,726.02), and Johan Wedell-Wedellsborg ($1,325,003.84). How much insider buying is happening at Y-mAbs Therapeutics? Insiders have purchased a total of 325,139 YMAB shares in the last 24 months for a total of $2,395,729.86 bought. Which Y-mAbs Therapeutics insiders have been selling company stock? The following insiders have sold YMAB shares in the last 24 months: Bo Kruse ($378,647.97), Gerard Ber ($8,664.00), Joris Wilms ($73,450.00), Thomas Gad ($3,138,263.00), and Vignesh Rajah ($28,282.83). How much insider selling is happening at Y-mAbs Therapeutics? Insiders have sold a total of 376,155 Y-mAbs Therapeutics shares in the last 24 months for a total of $3,627,307.80 sold. Y-mAbs Therapeutics Key ExecutivesMr. Thomas Gad (Age 53)Founder, Chief Business Officer & Vice Chairman Compensation: $1.05M3 recent tradesMr. Bo Kruse (Age 51)Executive VP, Secretary, Treasurer & CFO Compensation: $685.02k1 recent tradesMs. Susan Smith (Age 53)Senior VP & Chief Commercial Officer Compensation: $710kMr. Michael Rossi (Age 53)CEO, President & Director Mr. Joris Wiel Jan Wilms (Age 50)Senior VP & COO Dr. Torben Lund-Hansen M.Sc. (Age 73)Ph.D., Senior VP & CTO Dr. Steen Lisby M.D. (Age 60)M.Sc., Senior VP & Chief Scientific Officer Compensation: $393.99kMs. Courtney DuganVice President of Investor RelationsDr. Vignesh Rajah M.B.A. (Age 59)MBBS, Senior VP & Chief Medical Officer Compensation: $406.27k More Insider Trading Tools from MarketBeat Related Companies MRSN Insider Trading AMRN Insider Trading HRTX Insider Trading GBIO Insider Trading AUPH Insider Trading TARS Insider Trading ARVN Insider Trading XNCR Insider Trading RXRX Insider Trading IMCR Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Selling Into 3 Rallies: Investors Should Do the OppositeInsiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking On This page (NASDAQ:YMAB) was last updated on 11/25/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
